Suzanne Caruso
Bio
I’ve spent more than 15 years helping pharmaceutical companies plan and operationalize clinical trials, with leadership roles across Novartis, GSK, WCG, Veeva and now Norstella. Having worked across clinical operations, data and strategic intelligence, I’ve seen firsthand where AI can remove friction from development and where human expertise remains essential.
What makes Norstella’s AI different?
We start with decades of proprietary clinical, pipeline and real-world data that is already organized around how drug development actually works. That foundation gives our AI the context to address industry-specific questions, while transparent sourcing and expert oversight help teams understand where insights come from and how they were generated.
What can pharma teams do now that was not possible two years ago?
AI agents can now manage many of the manual steps between a question and a decision, helping teams move from fragmented data to a sourced, evidence-based answer in minutes rather than days. Teams can also use AI and real-world data to test study assumptions, identify patients and refine recruitment strategies at a speed and scale that was not previously practical.
How can AI accelerate the journey from pipeline to patient?
Drug development is full of handoffs between people, systems and decisions, and every one of those handoffs can create delay. AI can help connect those workflows, automate routine analysis and surface the right insights at the right time, allowing experts to focus on the decisions that matter most and helping promising therapies reach patients sooner.